Dr. Joseph J. Buggy, Ph.D., is Vice President Research of Pharmacyclics, Inc., since September 2007. From May 2006 to August 2007, Dr. Buggy served as Senior Director, Research at Pharmacyclics. From November 2001 to April 2006, he served as Director, Department of Biology at Celera Genomics, a biotechnology company. From June 1996 to October 2001, he was a staff scientist at AXYS Pharmaceuticals, Inc., a biotechnology company. Prior to that Dr. Buggy worked as a scientist at Bayer Corporationrationration in West Haven, CT
Buggy received a Ph.D. in Molecular, Cellular, and Developmental Biology from Indiana University and a B.S. degree in Microbiology from the University of Pittsburgh.
Management Efficency
The company has return on total asset (ROA) of 31.72 % which means that it generated profit of $31.72 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 66.49 % meaning that it created $66.49 on every $100 dollars invested by stockholders.
Pharmacyclics, Inc., a clinicalstage biopharmaceutical company, focuses on the development and commercialization of smallmolecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Inc [PCYC] is traded on Nasdaq Capital Markets in USA. It is located in Sunnyvale, CA and employs 247 people. Filter other
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
Report was successfully generated.
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory
Nasdaq Pharmacyclics Inc
-0.06% 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Advice
